Erratum: Effects of the Src kinase inhibitor saracatinib (AZD0530) on bone turnover in healthy men: A randomized, double‐blind, placebo‐controlled, multiple‐ascending‐dose phase I trial

Age, years 32.6 (10.0) 34.6 (7.6) 35.0 (13.8) 37.4 (7.2) 28.7 (9.7) 37.5 (7.8) Height, cm 178.3 (7.9) 177.2 (8.2) 175.2 (4.7) 177.6 (6.4) 183.6 (5.5) 178.6 (7.2) Weight, kg 80.3 (11.6) 77.9 (12.6) 77.6 (10.2) 80.2 (9.1) 85.3 (9.1) 85.0 (10.2) Body mass index, kg/m 25.2 (2.3) 24.7 (2.6) 25.3 (3.5) 25.3 (1.6) 25.3 (2.6) 26.6 (2.0) BTM sCTX, ng/mL 0.588 (0.274) 0.644 (0.379) 0.542 (0.288) 0.578 (0.217) 0.701 (0.418) 0.496 (0.186) uNTX/Cr, nmolBCE/mmol 34.8 (16.7) 41.4 (33.9) 46.3 (34.8) 33.0 (7.1) 43.6 (32.1) 30.6 (11.3) TRAcP-5b, U/L 3.02 (0.38) 3.42 (0.91) 3.35 (0.68) 3.12 (0.78) 4.06 (1.57) 3.13 (0.52) PINP, ng/mL 59.2 (26.0) 57.3 (33.5) 62.0 (37.9) 55.1 (21.0) 80.2 (57.0) 50.4 (18.5) Bone ALP, ng/mL 15.2 (3.6) 13.7 (4.6) 12.6 (3.8) 11.4 (1.4) 14.1 (5.0) 11.7 (3.8)